By pairing systemic neutralization with therapies that specifically induce local CXCL10 production (such as oncolytic viruses or localized radiotherapy as described above), clinicians could artificially generate a steep chemotactic gradient that strongly favors immune infiltration to the primary tumor site. Here, CXCL10 is linked to neoplasm.